Long-Term IGF-1 Treatment Explored for Children with Primary Growth Failure
Background
Children diagnosed with Primary IGF-1 Deficiency (PIGFD), a rare genetic condition, experience severe growth failure due to their bodies' inability to produce sufficient Insulin-Like Growth Factor-1 (IGF-1), a crucial hormone for normal growth and development. While recombinant human IGF-1 (rhIGF-1), known as mecasermin (Increlex), is an approved therapy, there remains a critical need for comprehensive data on its long-term safety and efficacy, particularly regarding optimal dosing strategies in this vulnerable pediatric population.
Study Design
Results
This Phase 3 extension study (NCT00330668) was unfortunately terminated in March 2010, as indicated by the clinical trial record. Consequently, the provided research documentation does not contain specific efficacy or safety results regarding the long-term impact of rhIGF-1 on growth parameters, adverse events, or other clinical outcomes in children with Primary IGF-1 Deficiency. Therefore, quantitative data, such as growth velocity improvements or specific side effect profiles, are not available from this particular study record. This Phase 3 extension study was terminated in March 2010, preventing the collection of long-term efficacy and safety data from this specific trial record.
Why It Matters
Despite its termination, this study highlights the ongoing effort to understand and optimize treatments for Primary IGF-1 Deficiency, a condition causing significant growth failure in children. The intent was to gather crucial long-term data on rhIGF-1 (mecasermin), an already approved therapy (Increlex), to refine dosing and assess sustained benefits and safety. Such long-term studies are vital for establishing comprehensive treatment guidelines and improving the quality of life for pediatric patients with chronic growth disorders. Even terminated trials can provide valuable insights into trial design, patient recruitment challenges, and the feasibility of complex dosing regimens, informing future clinical development and potentially leading to more effective clinical use.